Stock listing
ASX:PYC PYC Therapeutics Limited Share Price
Home listing (ASX) of PYC Therapeutics Limited
Follow PYC Therapeutics Limited into a list and get an email when it puts out news.
Share price · ASX:PYC
$1.65 AUD -0.09 (-5.2%)
Close on Nov 20, 2026
- Day range
- $1.60 – $1.67 AUDNov 20, 2026
- Volume
- 5.10M sharesNov 20, 2026
- Market cap
- $1.62B AUDAt the close on Nov 20, 2026 · price × 984.2M shares outstanding
- 52-week range
- $1.05 – $2.93 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $9.49M AUDMedian day 2.87M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:PYC · Home | $1.645 AUD | -0.09 (-5.2%) | 5,097,493 | $1.625 | $1.673 | $1.598 | $1.735 | Close on Nov 20, 2026 |
| OTC:PYCXF | $1.219 USD | -0.031 (-2.5%) | 900 | $1.219 | $1.219 | $1.219 | $1.25 | Close on Nov 13, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:PYC · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.645 | -0.09 | -5.2% | $1.625 | $1.673 | $1.598 | 5,097,493 | |
| $1.735 | +0.01 | +0.6% | $1.735 | $1.80 | $1.715 | 2,852,169 | |
| $1.725 | -0.065 | -3.6% | $1.77 | $1.81 | $1.678 | 3,427,933 | |
| $1.79 | -0.045 | -2.5% | $1.86 | $1.86 | $1.775 | 2,047,132 | |
| $1.835 | -0.08 | -4.2% | $1.90 | $1.915 | $1.82 | 2,539,508 | |
| $1.915 | +0.01 | +0.5% | $1.905 | $1.955 | $1.86 | 2,258,949 | |
| $1.905 | -0.09 | -4.5% | $1.97 | $1.97 | $1.903 | 2,577,728 | |
| $1.995 | +0.005 | +0.3% | $1.99 | $2.04 | $1.91 | 3,635,539 | |
| $1.99 | +0.11 | +5.9% | $1.87 | $2.01 | $1.865 | 1,771,481 | |
| $1.88 | -0.05 | -2.6% | $1.84 | $1.925 | $1.788 | 2,388,206 | |
| $1.93 | +0.08 | +4.3% | $1.92 | $1.96 | $1.88 | 3,999,324 | |
| $1.85 | +0.05 | +2.8% | $1.775 | $1.885 | $1.77 | 3,924,895 | |
| $1.80 | -0.10 | -5.3% | $1.845 | $1.875 | $1.758 | 2,585,037 | |
| $1.90 | +0.02 | +1.1% | $1.87 | $2.00 | $1.84 | 2,774,166 | |
| $1.88 | -0.055 | -2.8% | $1.93 | $1.93 | $1.855 | 4,194,530 | |
| $1.935 | -0.035 | -1.8% | $1.975 | $1.993 | $1.91 | 2,878,124 | |
| $1.97 | +0.05 | +2.6% | $1.93 | $2.005 | $1.905 | 3,130,589 | |
| $1.92 | +0.165 | +9.4% | $1.75 | $1.93 | $1.75 | 4,365,632 | |
| $1.755 | -0.025 | -1.4% | $1.75 | $1.78 | $1.715 | 4,563,687 | |
| $1.78 | -0.03 | -1.7% | $1.83 | $1.83 | $1.703 | 2,890,704 | |
| $1.81 | +0.01 | +0.6% | $1.82 | $1.83 | $1.76 | 1,956,748 | |
| $1.80 | +0.02 | +1.1% | $1.805 | $1.84 | $1.735 | 2,099,987 | |
| $1.78 | -0.03 | -1.7% | $1.83 | $1.83 | $1.735 | 2,566,944 | |
| $1.81 | -0.10 | -5.2% | $1.88 | $1.895 | $1.792 | 1,938,021 | |
| $1.91 | +0.06 | +3.2% | $1.86 | $1.915 | $1.79 | 2,442,045 | |
| $1.85 | -0.13 | -6.6% | $1.96 | $1.96 | $1.80 | 3,402,571 | |
| $1.98 | -0.16 | -7.5% | $2.05 | $2.11 | $1.975 | 3,435,658 | |
| $2.14 | -0.25 | -10.5% | $2.36 | $2.39 | $2.11 | 4,108,882 | |
| $2.39 | -0.06 | -2.4% | $2.45 | $2.51 | $2.39 | 2,192,220 | |
| $2.45 | -0.08 | -3.2% | $2.52 | $2.52 | $2.39 | 2,689,888 | |
| $2.53 | +0.06 | +2.4% | $2.49 | $2.54 | $2.425 | 2,601,344 | |
| $2.47 | -0.21 | -7.8% | $2.70 | $2.73 | $2.46 | 7,175,628 | |
| $2.68 | +0.13 | +5.1% | $2.60 | $2.71 | $2.59 | 3,075,321 | |
| $2.55 | +0.09 | +3.7% | $2.47 | $2.63 | $2.44 | 1,367,849 | |
| $2.46 | -0.05 | -2.0% | $2.55 | $2.56 | $2.44 | 1,219,518 | |
| $2.51 | -0.17 | -6.3% | $2.66 | $2.67 | $2.49 | 1,677,046 | |
| $2.68 | -0.09 | -3.2% | $2.80 | $2.815 | $2.67 | 3,741,769 | |
| $2.77 | +0.02 | +0.7% | $2.75 | $2.84 | $2.74 | 3,147,785 | |
| $2.75 | -0.07 | -2.5% | $2.80 | $2.80 | $2.70 | 2,130,618 | |
| $2.82 | -0.09 | -3.1% | $2.83 | $2.87 | $2.80 | 1,207,356 | |
| $2.91 | +0.07 | +2.5% | $2.78 | $2.91 | $2.78 | 8,402,265 | |
| $2.84 | -0.04 | -1.4% | $2.87 | $2.88 | $2.75 | 1,849,823 | |
| $2.88 | +0.09 | +3.2% | $2.83 | $2.90 | $2.725 | 5,477,742 | |
| $2.79 | +0.12 | +4.5% | $2.58 | $2.93 | $2.58 | 8,163,885 | |
| $2.67 | +0.27 | +11.3% | $2.43 | $2.67 | $2.42 | 51,841,254 | |
| $2.40 | +0.15 | +6.7% | $2.25 | $2.40 | $2.20 | 2,866,025 | |
| $2.25 | -0.01 | -0.4% | $2.34 | $2.35 | $2.23 | 1,772,350 | |
| $2.26 | +0.03 | +1.3% | $2.27 | $2.31 | $2.23 | 4,137,330 | |
| $2.23 | -0.07 | -3.0% | $2.30 | $2.30 | $2.19 | 2,889,364 | |
| $2.30 | -0.02 | -0.9% | $2.32 | $2.34 | $2.26 | 3,180,085 | |
| $2.32 | -0.10 | -4.1% | $2.44 | $2.46 | $2.29 | 2,663,026 | |
| $2.42 | -0.08 | -3.2% | $2.48 | $2.50 | $2.41 | 4,360,668 | |
| $2.50 | -0.01 | -0.4% | $2.51 | $2.54 | $2.46 | 3,014,564 | |
| $2.51 | +0.02 | +0.8% | $2.59 | $2.60 | $2.465 | 3,301,375 | |
| $2.49 | -0.08 | -3.1% | $2.58 | $2.59 | $2.47 | 3,347,904 | |
| $2.57 | +0.14 | +5.8% | $2.45 | $2.62 | $2.43 | 3,992,122 | |
| $2.43 | +0.14 | +6.1% | $2.30 | $2.43 | $2.27 | 10,751,807 | |
| $2.29 | -0.03 | -1.3% | $2.32 | $2.35 | $2.27 | 7,476,947 | |
| $2.32 | +0.07 | +3.1% | $2.30 | $2.32 | $2.21 | 8,641,108 | |
| $2.25 | -0.01 | -0.4% | $2.21 | $2.31 | $2.20 | 1,548,143 | |
| $2.26 | +0.09 | +4.1% | $2.20 | $2.28 | $2.11 | 2,391,608 | |
| $2.17 | +0.09 | +4.3% | $2.10 | $2.19 | $2.09 | 1,360,907 | |
| $2.08 | -0.02 | -1.0% | $2.09 | $2.105 | $2.04 | 1,361,994 | |
| $2.10 | +0.03 | +1.4% | $2.10 | $2.15 | $2.05 | 2,019,395 | |
| $2.07 | -0.13 | -5.9% | $2.19 | $2.20 | $2.05 | 2,827,588 | |
| $2.20 | +0.05 | +2.3% | $2.16 | $2.225 | $2.15 | 1,520,843 |
Splits
3 splits since 2019 · ASX:PYC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 85-for-83 | Split | |
| 1-for-10 | Consolidation | |
| 53-for-52 | Split |
- Ticker
- ASX:PYC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 12, 2026
PKD Program - Enrolment Target Met
Latest deck · Nov 12, 2026
Shareholder Meeting (November 2026)
Shareholder meeting · 37 slides
Latest news
PKD Program - Enrolment Target Met
Nov 12, 2026
Closed $1.84 (-4.2%) on Nov 13, 2026
Results of Annual General Meeting
Nov 11, 2026
Closed $1.92 (+0.5%) on Nov 12, 2026
2026 Annual General Meeting Program and CEO Presentation
Nov 11, 2026
Closed $1.92 (+0.5%) on Nov 12, 2026
Notification regarding unquoted securities - PYC
Nov 9, 2026
Closed $2.00 (+0.3%) on Nov 10, 2026
Change of Director's Interest Notice
Nov 5, 2026
Closed $1.88 (-2.6%) on Nov 6, 2026
Annual General Meeting - Conference Link
Nov 4, 2026
Closed $1.93 (+4.3%) on Nov 5, 2026
Exercise of Options and Cleansing Notice
Oct 29, 2026
Closed $1.88 (-2.8%) on Oct 30, 2026
Application for quotation of securities - PYC
Oct 29, 2026
Closed $1.88 (-2.8%) on Oct 30, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 28, 2026
Closed $1.94 (-1.8%) on Oct 29, 2026
PKD Program - ASN Presentation
Oct 22, 2026
Closed $1.78 (-1.7%) on Oct 23, 2026
PYC Therapeutics Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 49 in the last 12 months · 284 in all · newest Nov 12, 2026 · oldest 2016
- Decks
- 102 decks · latest Nov 12, 2026
Where PYC Therapeutics Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:PYC · Home listing · This page | ASX | Australia | AUD |
| OTC:PYCXF | OTC | United States | USD |
Valuation
Price/book 2.3× against a median of 4.5×: 4th lowest of 11 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.17B AUD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PYC Therapeutics Limited · ASX:PYC | US$1.07B | US$775.8M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Ascentage Pharma Group International · HKEX:6855 | US$1.11B | US$1.14B | n/a | 13.7× | n/a | 13.4× | −216.5% | 3.8× | n/a |
| Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321 | US$1.10B | US$1.10B | 102× | 6.8× | n/a | 2.9× | 6.6% | 0.5× | n/a |
| Pharma Mar SA · BME:PHM | US$1.10B | US$978.5M | 14.6× | 3.8× | 16.6× | 4.2× | 28.8% | 0.3× | n/a |
| Alpha Tau Medical Ltd · NASDAQ:DRTS | US$1.09B | US$1.00B | n/a | n/a | n/a | 55.3× | n/a | 0.8× | 1.89 |
| Kardigan, Inc. · NASDAQ:KARD | US$1.08B | US$621.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Jade Biosciences, Inc. · NASDAQ:JBIO | US$1.06B | US$583.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.14 |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Nektar Therapeutics · NASDAQ:NKTR | US$1.03B | US$492.8M | n/a | 9.4× | n/a | 1.2× | −339.7% | 0.1× | 1.28 |
| Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062 | US$1.02B | US$984.8M | n/a | 9.2× | n/a | 9.5× | −146.4% | 2.9× | n/a |
| SpyGlass Pharma, Inc. · NASDAQ:SGP | US$1.02B | US$809.5M | n/a | n/a | n/a | 4.8× | n/a | 0.0× | 1.01 |
| Median of the others | US$1.07B | US$981.7M | 58.5× | 9.3× | 16.6× | 4.5× | −137.6% | 0.4× | 1.21 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.07 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.082 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rohan Hockings | Executive Director & Chief Executive Officer |
| Thomas Ulmer | Chief Financial Officer |
| Garrett Bray | Chief Operating Officer |
| Jonathan Riley | General Counsel |
| Candice Junge | Chief Clinical Development Officer |
| Janya Grainok | Chief Scientific Officer |
| Paula Cunningham | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Peter Coleman | Independent Non-Executive Chair |
| Ian Constable | Non-Executive Director |
| Rohan Hockings | Executive Director & Chief Executive Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Aug 27, 2025 · Before open | −0.4% |
| Q2 2025 | Feb 27, 2025 | +2.9% |
| Q2 2023 | Feb 28, 2023 · After close | +2.6% |
| Q4 2022 | Sep 23, 2022 · Before open | −3.9% |
| Q2 2022 | Feb 28, 2022 | −2.9% |
| Q4 2021 | Aug 31, 2021 | +3.3% |
| Q2 2021 | Feb 26, 2021 | +3.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (November 2026) | Shareholder meeting | 37 slides | Nov 12, 2026 |
| American Society of Nephrology (ASN) Kidney Week 2026 | Conference | 14 slides | Oct 23, 2026 |
| EURetina 2026 | Conference | 19 slides | Oct 2, 2026 |
| Investor Presentation (September 2026) | Investor deck | 17 slides | Sep 4, 2026 |
| Neuro-Ophthalmology Society of Australia (NOSA) Annual Scientific Meeting 2026 | Conference | 16 slides | Sep 3, 2026 |
| 2026 PMS Foundation Family Conference | Conference | 19 slides | Jul 20, 2026 |
| Corporate Update (May 2026) | Corporate update | 19 slides | May 22, 2026 |
| ARVO 2026 | Conference | 70 slides | May 4, 2026 |
| North American Neuro-Ophthalmology Society (NANOS) 2026 Conference | Conference | 16 slides | Mar 24, 2026 |
| Investor Presentation (February 2026) | Investor deck | 65 slides | Feb 2, 2026 |
Show 50 decks
This page holds 50 of 102 decks. Open Decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Rights offering of new fully paid ordinary shares (retail entitlement offer) Closed: A$47M in the latest tranche · A$1.5 a share · E&P Capital Pty Ltd +2 Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Bloom Burton Securities Inc. (co-lead) Use of proceeds: Advance PYC-003, PYC-002, VP-001 and PYC-001 drug candidates toward registrational or first-in-human trials, plus working capital, R&D and costs | Mar 4, 2026 | |
| Private placement of fully paid ordinary shares Closed: A$128M raised · A$1.5 a share · Bloom Burton Securities Inc. Dealers: Bloom Burton Securities Inc. (lead) Buyers: RA Capital Management; Perceptive Advisors; Driehaus Capital Management; MPM BioImpact; Rock Springs Capital; RTW Investments Use of proceeds: Extend cash runway through CY2030 to deliver human safety and efficacy data for all four drug development programs | Feb 4, 2026 | US$89.6M |
| Rights offering of new fully paid ordinary shares Announced: about A$145.8M · A$1.25 a share · E&P Capital Pty Ltd +6 Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Custom Binders Pty Ltd, John Baird, Sami Zouad, Adrian Bonaddio, Dr Yang Sheng Yeo & Ms Esther Mei Yen Liaw as trustees for the Papy Family Trust Buyers: Alan Tribe (intends to subscribe for New Shares with a value of A$35 million) Insiders: Chairman Alan Tribe, holding 34% of shares, intends to subscribe for New Shares with a value of A$35 million Use of proceeds: Advance blinding eye disease, polycystic kidney disease and Phelan-McDermid Syndrome drug candidates through human trials; working capital and offer costs | Feb 17, 2025 | US$92.69M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.5M | 22.1M | 15.8M | 16.0M | 3.07M | 2.40M | 250 | 48.5K | 2.76M | |
| Cost of revenue | 1.20M | 1.12M | 1.07M | 882.0K | 839.5K | 622.4K | 547.1K | 130.6K | 81.3K | 4.67M |
| Gross profit | -1.20M | 23.5M | 22.1M | 14.9M | 15.2M | 2.45M | 1.85M | -130.6K | -32.8K | -1.91M |
| Research and development | 74.0M | 70.1M | 56.4M | 35.1M | 24.0M | 14.0M | 5.88M | 4.51M | 6.96M | 4.67M |
| Selling, general and administrative | 6.69M | 7.07M | 4.51M | 4.09M | 6.30M | 7.83M | 3.82M | 409.8K | 1.16M | 1.04M |
| Operating income | -82.7M | -53.6M | -38.9M | -39.2M | -30.2M | -21.8M | -9.70M | -7.10M | -9.77M | -4.25M |
| Depreciation and amortization | 1.20M | 1.12M | 1.07M | 882.0K | 839.5K | 622.4K | 547.1K | 130.6K | 81.3K | 55.3K |
| EBITDA | -81.5M | -52.5M | -37.8M | -38.3M | -29.4M | -21.2M | -9.15M | -6.97M | -9.69M | -4.20M |
| Interest expense | 40.5K | 62.2K | 49.2K | 27.3K | 32.6K | 38.8K | 42.9K | 118.2K | 0 | 0 |
| Income before tax | -69.8M | -51.0M | -55.7M | -39.2M | -30.3M | -21.7M | -9.48M | -6.98M | -9.60M | -4.18M |
| Income tax | -26.0M | -23.5M | -17.6M | -15.8M | -16.0M | -3.07M | -2.40M | -2.90M | -2.17M | -2.22M |
| Net income | -43.3M | -50.3M | -37.7M | -22.8M | -13.9M | -17.8M | -6.82M | -4.08M | -7.43M | -1.95M |
| Earnings per share, basic | -0.06 | -0.10 | -0.01 | -0.01 | -0.00 | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 53.6M | 153.1M | 66.9M | 15.6M | 29.1M | 18.4M | 7.24M | 1.66M | 3.15M | 9.94M |
| Short-term investments | 394.0M | 0 | 33.1M | 18.2M | 4.52M | |||||
| Receivables | 34.1M | 24.1M | 18.0M | 16.3M | 10.1M | 185.6K | 82.7K | 10.8K | 18.5K | 192.2K |
| Inventory | -18.0M | -42.7K | -10.8K | -192.2K | ||||||
| Current assets | 482.2M | 177.5M | 85.6M | 31.9M | 39.2M | 51.8M | 25.6M | 6.22M | 3.28M | 10.1M |
| Property, plant and equipment | 1.90M | 1.57M | 1.04M | 1.63M | 1.49M | 1.14M | 482.9K | 143.4K | 216.1K | |
| Total assets | 708.5M | 183.3M | 91.2M | 37.2M | 45.4M | 57.9M | 31.5M | 6.70M | 3.42M | 10.3M |
| Accounts payable | 9.89M | 8.75M | 7.53M | 4.92M | 2.57M | 2.35M | 97.3K | 193.7K | 1.68M | 1.45M |
| Current liabilities | 14.4M | 12.3M | 9.11M | 8.41M | 4.39M | 3.30M | 705.6K | 401.9K | 1.77M | 1.49M |
| Total debt | 625.0K | 1.02M | 1.11M | 315.5K | 943.8K | 730.4K | 798.1K | 798.1K | ||
| Total liabilities | 15.2M | 13.3M | 10.2M | 8.72M | 5.15M | 4.02M | 1.35M | 401.9K | 1.77M | 1.49M |
| Shareholders' equity | 693.3M | 169.6M | 80.5M | 27.7M | 39.4M | 53.0M | 28.5M | 6.30M | 1.65M | 8.86M |
| Shares outstanding | 732.6M | 500.5M | 3.94B | 3.25B | 3.22B | 3.13B | 2.80B | 2.80B | 2.22B | 2.01B |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -44.5M | -51.6M | -38.6M | -24.4M | -21.8M | -11.8M | -5.75M | -5.13M | -6.71M | -1.88M |
| Capital spending | -531.4K | -975.4K | -307.0K | -491.1K | -386.9K | -591.0K | -106.1K | -457.5K | -210.6K | -4.54K |
| Free cash flow | -45.1M | -52.5M | -38.9M | -24.9M | -22.2M | -12.4M | -5.85M | -5.58M | -6.92M | -1.89M |
| Cash from investing | -616.2M | -975.4K | -307.0K | -477.1K | 32.7M | -15.5M | -13.8M | -4.98M | -210.6K | -3.46K |
| Cash from financing | 563.2M | 138.7M | 90.2M | 11.4M | -182.4K | 38.6M | 25.1M | 8.62M | 125.2K | 4.75M |
| Dividends paid | -10.5M | -36.3M | -23.5M | |||||||
| Share buybacks | -36.6M | -6.80M | -1.57M | -976.2K | -976.2K | -2.29M | -1.62M | -503.2K | -9.82K | -313.3K |
| Change in cash | -99.5M | 86.2M | 51.3M | -13.5M | 10.7M | 11.2M | 1.06M | -1.49M | -6.79M | 2.87M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PKD Program - Enrolment Target Met | Nov 12, 2026 | Other filings | ASX |
| Results of Annual General Meeting | Nov 11, 2026 | Meeting outcome | ASX |
| 2026 Annual General Meeting Program and CEO Presentation | Nov 11, 2026 | Meeting notice | ASX |
| Notification regarding unquoted securities - PYC | Nov 9, 2026 | Other filings | ASX |
| Change of Director's Interest Notice | Nov 5, 2026 | Ownership change notice | ASX |
| Annual General Meeting - Conference Link | Nov 4, 2026 | Meeting notice | ASX |
| Change of Director's Interest Notice | Nov 3, 2026 | Ownership change notice | ASX |
| Change of Director's Interest Notice | Oct 30, 2026 | Ownership change notice | ASX |
| Exercise of Options and Cleansing Notice | Oct 29, 2026 | Financing | ASX |
| Application for quotation of securities - PYC | Oct 29, 2026 | Financing | ASX |
Show 200 filings
This page holds 200 of 284 filings. Open Filings
Cap table
Built by 6ix from PYC Therapeutics Limited’s releases · as of Mar 4, 2026
- Common shares
- 984,210,447
- Fully diluted
- 984,210,447
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 984,210,447 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 984,210,447 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Candice Junge | Chief Clinical Development Officer · Since at least Nov 5, 2026 |
| Garrett Bray | Chief Operating Officer · Since at least Nov 5, 2026 |
| Ian Constable | Non-Executive Director · Since at least Nov 5, 2026 |
| Janya Grainok | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Jonathan Riley | General Counsel · Since at least Nov 5, 2026 |
| Paula Cunningham | Chief Development Officer · Since at least Nov 5, 2026 |
| Peter Coleman | Independent Non-Executive Chair · Since at least Nov 5, 2026 |
| Rohan Hockings | Executive Director & Chief Executive Officer · Since at least Nov 5, 2026 |
| Thomas Ulmer | Chief Financial Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about PYC Therapeutics Limited.